Although overall RUNX1 levels in bone marrow plasma cells did not differ significantly between MM patients and controls, the marked upregulation in the plasmablast subset suggests a potential pathogenic role for RUNX1 at an earlier stage of malignant differentiation. Here, RUNX1 is linked to Miyoshi myopathy.